Images List Premium Download Classic

Isoquinolin

Isoquinolin-related patent applications - as published by the U.S. Patent and Trademark Office (USPTO).


loading
Phenyl tetrahydroisoquinoline compound substituted with heteroaryl
July 27, 2017 - N°20170210736

Y represents a hydrogen atom or a structure represented by the following formula [3′]:
Redoxindicators
Roche Diagnostics Operations, Inc.
July 06, 2017 - N°20170191990

The present invention relates to a chemical compound or a salt or solvate thereof being a phenazine-, phenanthridine-, phenanthroline-, quinoline-, quinoxaline-, acridine- isoquinoline-, pyrazine- or pyridine-derivative comprising a conjugated π-system and a π-acceptor group, and to uses thereof. The present invention further relates to a chemistry matrix and to a test element comprising the chemical compound ...
Crystalline salts of (s)-6-((1-acetylpiperidin-4-yl)amino)-n-(3-(3,4-dihydroisoquinolin-2(1h)-yl)-2...
Glaxosmithkline Intellectual Property Development Limited
July 06, 2017 - N°20170190688

Disclosed are novel crystalline salts of (s)-6-((1-acetylpiperidin-4-yl)amino)-n-(3-(3,4-dihydroisoquinolin-2(1h)-yl)-2-hydroxypropyl)pyrimidine-4-carboxamide and pharmaceutical compositions containing the same. Also disclosed are processes for the preparation thereof and methods for use thereof.
Isoquinolin Patent Pack
Download + patent application PDFs
Isoquinolin Patent Applications
Download + Isoquinolin-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Isoquinolin-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Tetrahydroisoquinolin-1-one derivative or salt thereof
Seldar Pharma Inc.
July 06, 2017 - N°20170189390

To provide a pharmaceutical, in particular a compound which can be used as a therapeutic agent for irritable bowel syndrome (ibs). It was found that a tetrahydroisoquinolin-1-one derivative having an amide group at the 4-position or a pharmaceutically acceptable salt thereof has an excellent bombesin 2 (bb2) receptor antagonistic action. It is also found that the tetrahydroisoquinolin-1-one derivative is ...
Biisoquinoline compounds and methods of treatment
University Of Florida Research Foundation
June 29, 2017 - N°20170183349

The instant invention describes biisoquinoline compounds having therapeutic activity, and methods of treating dis-orders such as cancer, tumors and cell proliferation related disorders, or affect cell differentiation, dedifferentiation or transdifferentiation.
Synthetic methods for preparation of (s)-(2r,3r,11br)-3-isobutyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1h-pyrido[2,1...
Neurocrine Biosciences, Inc.
June 29, 2017 - N°20170183346

Provided herein are processes for the preparation of (s)-(2r,3r,11br-3-isobuty-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1h-pyrido[2,1-a]isoquinolin-2-yl 2-amino-3-methylbutanoate di(4-methylbenzenesulfonate), or a solvate, hydrate, or polymorph thereof.
Isoquinolin Patent Pack
Download + patent application PDFs
Isoquinolin Patent Applications
Download + Isoquinolin-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Isoquinolin-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Polymerizable liquid crystal compound, composition, liquid crystal polymerization film-kind thereof and use thereof
Takeda Pharmaceutical Company Limited
June 22, 2017 - N°20170174992

In which, in formula (1), g is a group composed of a quinoline skeleton, an isoquinoline skeleton, a quinoxaline skeleton or a quinazoline skeleton, a1 is 1,4-phenylene or 1,4-cyclohexylene, z1 is a connecting group, m is an integer from 0 to 3, and r1 is a group containing a polymerizable group.
Solid forms of substituted 5,6-dihydro-6-phenylbenzo[f]isoquinolin-2-amine compounds
Arqule, Inc.
June 22, 2017 - N°20170174636

The present application provides solid forms of (r)-6-(2-fluorophenyl)-n-(3-(2-(2-methoxyethylamino)ethyl)phenyl)-5,6-dihydrobenzo[h]quinazolin-2-amine dihydrochloride, and methods of preparing and using same.
Selective androgen receptor degrader (sard) ligands and methods of use thereof
University Of Tennessee Research Foundation
June 15, 2017 - N°20170166526

This invention provides novel indole, indazole, benzimidazole, indoline, quinolone, isoquinoline, and carbazole selective androgen receptor degrader (sard) compounds, pharmaceutical compositions and uses thereof in treating prostate cancer, advanced prostate cancer, castration resistant prostate cancer, other ar-expressing cancers, androgenic alopecia or other hyper androgenic dermal diseases, kennedy's disease, amyotrophic lateral sclerosis (als), abdominal aortic aneurysm (aaa), and uterine fibroids, and to ...
Method for a pesticide having an insecticide, acaricide and nematicide action based on isoquinoline alkaloids ...
Promotora Tecnica Industrial, S.a. De C.v.
June 08, 2017 - N°20170156345

The method for a pesticide having an insecticide, acaricide and nematicide action is obtained from plant extracts that have important synergic interactions in pesticide activity. The characteristics of the pesticide are efficient control of insects, mites and nematodes, low toxicity for mammals and low persistence in the environment. This pesticide is a composition based on plant extracts containing isoquinoline alkaloids ...
Tetrahydroisoquinolinone derivatives and their use in the inhibition of the hsp70 protein
Julius-maximilians-universitaet Wuerzburg
June 01, 2017 - N°20170152229

The present invention relates to tetrahydroisoquinolinone derivatives, a pharmaceutical composition comprising the same and the use of these derivatives in the inhibition of the hsp70 protein. The compounds are useful in the treatment or inhibition of cancer, autoimmune disease, rheumatoid arthritis, inflammatory bowel disease and psoriasis.
Benzylisoquinoline alkaloids (bia) producing microbes, and methods of making and using the same
Julius-maximilians-universitaet Wuerzburg
May 25, 2017 - N°20170145454

Aspects of the invention include host cells that are engineered to produce benzylisoquinoline alkaloids (bias). The host cells include heterologous coding sequences for a variety of enzymes involved in synthetic pathways from starting compounds to bias of the host cell. Also provided are methods of producing the bias of interest by culturing the host cells under culture conditions that promote ...
Isoquinolin Patent Pack
Download + patent application PDFs
Isoquinolin Patent Applications
Download + Isoquinolin-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Isoquinolin-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Valbenazine salts and polymorphs thereof
Julius-maximilians-universitaet Wuerzburg
May 25, 2017 - N°20170145008

Provided herein are salts of (s)-2-amino-3-methyl-butyric acid (2r,3r,11br)-3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2h-pyrido[2,1-a]isoquinolin-2-yl ester in amorphous and crystalline forms, and processes of preparation, and pharmaceutical compositions thereof. Also provided are methods of their use for treating, preventing, or ameliorating one or more symptoms of neurological disorders and diseases including hyperkinetic movement disorders ...
Pharmaceutical combinations
Julius-maximilians-universitaet Wuerzburg
May 25, 2017 - N°20170143723

The disclosure relates to a pharmaceutical combination of a mdm2/4 inhibitor, namely (s)-1-(4-chloro-phenyl)-7-isopropoxy-6-methoxy-2-(4-{methyl-[4-(4-methyl-3-oxo-piperazin-1-yl)-trans-cyclohexylmethyl]-amino}-phenyl)-1,4-dihydro-2h-isoquinolin-3-one or (s)-5-(5-chloro-1-methyl-2-oxo-1,2-dihydro-pyridin-3-yl)-6-(4-chloro-phenyl)-2-(2,4-dimethoxy-pyrimidin-5-yl)-1-isopropyl-5,6-dihydro-1h-pyrrolo[3,4-d]imidazol-4-one, and a cyclin dependent ...
Isoquinoline compounds, a process for their preparation, and pharmaceutical compositions containing them
Julius-maximilians-universitaet Wuerzburg
May 18, 2017 - N°20170137385

Medicinal products containing the same which are useful in treating or preventing pathologies which are the result of activation of the rhoa/rock pathway and phosphorylation of the myosin light chain.
Process and intermediates for the synthesis of (r)-praziquantel
Tongli Biomedical Co., Ltd.
May 04, 2017 - N°20170121330

The present disclosure relates to a process and new intermediates for the synthesis of (r)-praziquantel, which is obtained through four steps in proper order, that is, condensation reaction, reduction reaction, acylation reaction and ring-closing reaction, using (1r)-2-substituted-1,2,3,4-tetrahydroisoquinoline-1-carboxylic acid as starting material. Overall, the present disclosure provides a (r)-praziquantel product with higher optical purity through ...
New treatment
Verona Pharma Plc
April 27, 2017 - N°20170112839

The invention provides a compound for use in treating or preventing a disease or condition selected from cystic fibrosis, chronic obstructive pulmonary disease (copd), asthma, mild pulmonary disease, bronchitis, bronchiectasis, idiopathic bronchiectasis, allergic bronchopulmonary aspergillosis, sinusitis, rhinosinusitis, cftr-related metabolic syndrome (crms), pancreatitis, idiopathic chronic pancreatitis and sjörgren's syndrome, or for use in preventing male infertility caused by congenital ...
8-(piperazin-1-yl)-1,2,3,4-tetrahydro-isoquinoline derivatives
Actelion Pharmaceuticals Ltd
April 20, 2017 - N°20170107214

The invention relates to compounds of formula (i) wherein r1, r2, r3, r4 and r5 are as described in the description; to pharmaceutically acceptable salts thereof, and to the use of such compounds as medicaments, especially as modulators of the cxcr3 receptor.
Process for the preparation of (s)-2-((4r,4as,6r,7r,7ar,12bs)-7,9...
Noramco, Inc.
April 13, 2017 - N°20170101415

An invention includes a process for the preparation of (s)-2((4r,4as,6r,7r,7ar,12bs)-7,9-dimethoxy-1,2,3,4,5,6,7,7a-octahydro-4a,7-ethano-4,12-methanobenzofuro[3,2-e]isoquinolin-6-yl)-3,3-dimethylbutan-2-ol.
Therapeutic agent for ocular fundus disease
Kowa Company, Ltd.
April 13, 2017 - N°20170100409

Disclosed herein is a prophylactic or therapeutic agent for ocular fundus disease, especially diabetic retinopathy or age-related macular degeneration. The prophylactic or therapeutic agent for ocular fundus disease comprising: (s)-(−)-1-(4-fluoro-5-isoquinolinesulfonyl)-2-methyl-1,4-homopiperazine, a salt thereof, or a solvate thereof, as an active ingredient.
Loading